Engflag

Zep

Quick links to important sections

Zep

Zep_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zep

What is Zep? A Foundational Identity

Property Description
Active ingredient Clobazam and Omeprazole
Form Oral Tablets and Oral Suspension
Pharmacological class Benzodiazepine and Proton Pump Inhibitor (PPI)
General Purpose CNS Stabilization and Gastric Acid Suppression
Origin Synthetic

Zep, which represents a therapeutic product containing the active components Clobazam and Omeprazole, is a specialized prescription-only medication characterized by its dual pharmacological action across the neurological and gastrointestinal systems. This formulation is a synthetic compound administered via the oral route, designed to integrate two essential therapeutic needs into a single product identity.

What Type of Medicine is Zep? Classification and Composition

Zep is classified as a combination product that contains two distinct active pharmaceutical ingredients from separate classes: the anticonvulsant Clobazam and the antisecretory agent Omeprazole. Clobazam is identified as a 1,5-benzodiazepine derivative, a type of Central Nervous System (CNS) depressant, which increases inhibitory signaling via the GABA-A receptor. Clobazam is clinically recognized for its stabilizing properties in neurological conditions. Omeprazole belongs to the class of Proton Pump Inhibitors (PPIs). This unique combination addresses the need for both CNS stabilization and concurrent control of gastric acid secretion, making it distinct from single-agent formulations like the Clobazam brand Onfi or the Omeprazole brand Prilosec.

Understanding Zep's Dual Pharmacological Role

The general purpose of Zep is to deliver the calming effects of Clobazam on the nervous system while providing targeted acid suppression via Omeprazole. The Omeprazole component works by irreversibly deactivating the gastric proton pump, which minimizes the production of hydrochloric acid (HCl) in the stomach and reduces the amount of acid the stomach produces. This simultaneous action provides the general benefit of neurological stabilization paired with necessary gastric acid protection. Zep is available for oral administration in two primary dosage forms: oral tablets and an oral suspension, offering flexibility compared to formulations only available in solid form.

Regulatory References

  1. dual pharmacological action
  2. anticonvulsant
  3. NIH Review on Clobazam
  4. 1,5-benzodiazepine derivative
  5. Central Nervous System (CNS) depressant
  6. GABA-A receptor
  7. CNS stabilization
  8. oral suspension

What side effects are possible with Zep?

Possible Side Effects and Safety Information

The safety profile for Zep, combining Clobazam and Omeprazole, is defined by regulatory documents based on the known adverse reactions for each ingredient, classified by frequency and system-organ class. The most frequently documented adverse effects involve the Nervous System and the Gastrointestinal System.

Frequency Classification Representative Adverse Reactions
Very Common Headache (Omeprazole)
Common Somnolence, Sedation, Fatigue (Clobazam); Diarrhea, Abdominal pain (Omeprazole)
Uncommon Dizziness, Rash (Omeprazole)
Rare Psychotic disorder (Clobazam); Leukopenia (Omeprazole)

Serious Adverse Reactions and Duration-Related Safety

Regulatory labeling highlights specific serious adverse reactions. For the Clobazam component, risks include Profound Sedation and Respiratory Depression, as well as severe dermatological reactions like Stevens-Johnson Syndrome. For the Omeprazole component, serious risks include an increased risk of Bone Fracture, Hypomagnesemia, and Clostridium difficile-associated diarrhea.

Time-related patterns are noted in official documents. Effects such as somnolence and sedation are more common at the start of treatment or during dose escalation. Conversely, the risk of drug dependence and severe complications like bone fracture is associated with long-term exposure.

Population-Specific Safety: Older adults may be more susceptible to CNS-depressant effects and have an increased risk of bone fracture. Caution is explicitly advised for patients with Hepatic or Renal Impairment due to altered drug clearance.

Safety Restrictions: A documented constraint is the heightened risk of profound sedation when Clobazam is used concurrently with other CNS Depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section reflects documented descriptions of overdose and required emergency actions as stated in government regulatory sources for Zep (Clobazam and Omeprazole).

Documented Overdose Manifestations and Severe Outcomes

Overdose presentations include signs of central nervous system (CNS) depression, such as drowsiness, confusion, lethargy, and impaired coordination. Other documented effects include blurred vision, nausea, headache, and tachycardia.

Regulators emphasize that severe overdose, driven by the Clobazam component, carries the risk of profound sedation and respiratory depression, which may escalate to coma and death. This risk is specifically noted as increased when combined with other CNS depressants.

Official Emergency Actions and Management

Action Trigger Required Regulatory Action
Profound sedation or slow/difficult breathing Seek emergency medical care immediately
Suspected overdose Contact emergency services or a poison center

Treatment is defined as symptomatic and supportive, requiring careful monitoring of vital signs and protection of the patient’s airway. While the benzodiazepine-receptor antagonist Flumazenil may be considered, its efficacy for Clobazam overdose specifically is not consistently established. Furthermore, the official labeling states that no specific antidote for omeprazole overdosage is known, and omeprazole is not readily removed by dialysis.

Population Considerations

The regulatory labeling notes that altered metabolism in geriatric patients and those with hepatic impairment may increase sensitivity to the drug's effects, suggesting caution in overdose situations.

Therapeutic Uses of Zep

What Zep Treats: Main Uses and Benefits

Zep, which contains the active ingredient tirzepatide, is applied across key therapeutic domains to assist with maintaining functional stability. The medicine is relevant in contexts marked by increased discomfort related to metabolic challenges and is commonly used across conditions presenting with symptoms that interfere with daily functioning, including chronic weight management and Type 2 Diabetes Mellitus.

Addressing Chronic Weight Management

Zep is generally used across conditions presenting with symptoms that interfere with daily functioning related to excess weight, defined as obesity or being overweight with a related health issue (like high blood pressure or high cholesterol). It provides support that helps ease the overall symptom burden, and may assist with weight management, which contributes to improved comfort during symptomatic periods. The medicine is considered relevant in contexts involving heightened systemic burden where additional support for symptom management is needed.

Supporting the Management of Type 2 Diabetes

The medication is also applied in clinical settings that involve acute or unstable symptom patterns related to blood sugar in adults with Type 2 Diabetes Mellitus. It is relevant when short-term symptomatic assistance is needed to help with symptoms related to systemic imbalance, offering symptomatic relief that helps improve day-to-day comfort during symptomatic periods. The use of the medicine is also considered relevant in contexts involving Obstructive Sleep Apnoea (OSA) associated with obesity.

Quick Fact: Relief for Systemic Imbalance
Zep assists with symptoms related to systemic imbalance during episodes of heightened discomfort.

Regulatory References

  1. European Medicines Agency overview on Mounjaro (tirzepatide)

Eligibility and Restrictions for Use

Zep (tirzepatide) is approved for use in adults who have obesity or are overweight with at least one weight-related condition, or for those with moderate-to-severe obstructive sleep apnea and obesity. It is not approved for use in individuals with type 1 diabetes.

Contraindications and Cautions

Certain medical conditions and histories prevent or require caution when using Zep. The medication is contraindicated—meaning it should not be used—in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to a theoretical risk of thyroid C-cell tumors shown in animal studies. It is also contraindicated if a person has had a severe allergic reaction to tirzepatide or its ingredients.

Caution is advised for patients with a history of pancreatitis or severe gastrointestinal disease, such as severe gastroparesis. Individuals with a history of diabetic retinopathy, kidney problems, or mental health issues (like depression or suicidal ideation) should discuss these fully with their healthcare provider. Zep is not recommended during pregnancy or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zep (tirzepatide) has the potential to interact with certain other medicinal products, primarily through two documented mechanisms: an increased risk of low blood sugar when combined with other glucose-lowering agents, and a potential reduction in the absorption and effectiveness of some oral medications.

Interactions Affecting Blood Glucose

When Zep is used alongside other medicines that reduce blood sugar, such as insulin or insulin secretagogues (e.g., sulfonylureas), there is an increased risk of hypoglycemia (low blood sugar), which can be severe. In such cases, a dose reduction of the insulin or insulin secretagogue may be necessary to manage this additive effect.

Interactions Affecting Oral Medications

Zep is known to delay the time it takes for the stomach to empty. This effect can potentially impact the absorption of concurrently administered oral medications. This is particularly relevant for oral medicines that rely on a threshold concentration for their effectiveness or those with a narrow therapeutic index (where small changes in concentration can lead to significant changes in effect or safety, such as warfarin).

For oral hormonal contraceptives (birth control pills), the reduced absorption due to delayed gastric emptying may decrease their effectiveness. It is recommended to switch to a non-oral contraceptive method or to add a barrier method of contraception for a period of four weeks following the initiation of Zep and for four weeks after each dose increase.

Do-Not-Combine Rule

Co-administration of Zep with any other medicine containing tirzepatide or with any GLP-1 receptor agonist is not recommended.

Mechanism of Action

Mechanism of Action

The pharmacological action of Zep is defined by two highly specific molecular mechanisms targeting separate physiological systems: the CNS and the gastrointestinal tract.

Potentiation of CNS Inhibitory Signaling

Clobazam acts as a Positive Allosteric Modulator at the GABAA receptor. This interaction augments the effect of GABA, increasing the influx of chloride ions ( Cl^-) into the neuron. This results in cellular hyperpolarization and a reduction of neuronal depolarization potential.

Irreversible Blockade of Gastric Acid Secretion

Omeprazole is activated in the acidic environment of parietal cells and then forms a covalent bond with and permanently deactivates the H^+/ K^+- ATPase enzyme (the proton pump). This irreversible inhibition of the final pathway for H^+ ion secretion causes a sustained suppression of H^+ ion efflux, leading to an elevation of intragastric pH.

Metabolic Interaction

Omeprazole is an inhibitor of the CYP2C19 enzyme, which metabolizes Clobazam's primary active metabolite, N-desmethylclobazam. This metabolic slowdown increases the plasma concentration of the metabolite, sustaining GABA-ergic potentiation.

Dosage and Administration Information

How Zep is Used: Official Administration Guidelines

Zep, which contains the active components Clobazam and Omeprazole, is administered orally and must be used according to the specific instructions for its components. The dosing patterns and preparation requirements vary based on the active ingredient to ensure correct administration.

Administration Scope and Dosing

Feature Guideline
Route of administration Oral administration for all approved forms.
Clobazam Dosing (Adults) Initial dose is typically 10 mg once daily; maximum recommended dose is 40 mg daily.
Omeprazole Dosing Typical doses range from 20 mg to 40 mg once daily.

Frequency and Contextual Timing

The Clobazam component's administration frequency is defined by the dose size: doses of 10 mg or less are often taken once daily, while larger doses are generally administered in divided doses twice daily. The medicine's timing relative to food intake differs by component: Clobazam can be administered with or without food, but the Omeprazole component, which is a delayed-release formulation, must be taken before eating.

Procedural and Management Instructions

A structured approach is used for starting and stopping the Clobazam component. Dose increases are recommended to occur no more rapidly than weekly (titration) to allow for gradual adjustment. Crucially, the discontinuation of Clobazam must be a gradual withdrawal (tapering), typically achieved by reducing the total daily dose by 5 to 10 mg/day on a weekly basis. For older adults, the Clobazam component requires a lower initial starting dose of 5 mg daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zep

The following summary describes the types of research and the findings observed in clinical studies for Zep (tirzepatide), while maintaining a neutral and transparent perspective on the available evidence. Findings describe group patterns, not personal outcomes. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Evidence for use in Type 2 Diabetes Mellitus

The research base for Zep in Type 2 Diabetes is extensive, built primarily upon a series of large, global randomized controlled trials (RCTs) (e.g., the SURPASS program). These studies were applied in research contexts involving fluctuating or unstable symptoms related to blood sugar control. They included adults with the condition, many of whom were already managing their blood sugar with diet, exercise, or other pharmaceutical agents.

Researchers examined outcomes related to systemic or functional imbalance, primarily focusing on the long-term blood sugar marker Glycated Hemoglobin (HbA1c), which is an outcome monitoring physiological strain or stress. The trials also monitored changes in body weight from the start of the study. Research explored the patterns of HbA1c and body weight measurements over the study period.

Evidence for use in Chronic Weight Management

Clinical evidence for Zep in chronic weight management was studied for use in large randomized controlled trials (e.g., the SURMOUNT program). These studies included adults diagnosed with obesity or those who were overweight with at least one weight-related comorbidity. This research examined changes in outcomes related to systemic or functional imbalance, focusing on body weight.

The primary focus was on outcomes monitoring physiological strain or stress, including the mean percent change in body weight and the percentage of participants achieving specific weight reduction thresholds (e.g., 5% or 10% reduction). Studies observed these responses over defined time intervals, typically up to 72 or 88 weeks.

What Research Gaps and Uncertainties Remain

Evidence highlights what is known—and what is still uncertain—about Zep. One major area of uncertainty is the data for long-term cardiovascular outcomes, although major trials (like SURPASS-CVOT) are currently ongoing to address this. Additionally, while studies explored changes in outcomes related to physical discomfort over time, long-term effects are not fully established regarding the maintenance of these changes after treatment stops. Research provides context but not individual predictions, and because the follow-up durations were limited for certain endpoints, certainty remains low regarding the very long-term (multi-year) consequences.

Frequently Asked Questions (FAQ)

Common questions about Zep (FAQ)

Q: Does Zep need to be taken long-term?

A: The required duration of use is determined by the specific condition being treated. For the Clobazam component, official regulatory documents indicate that long-term use carries warnings about the risk of drug dependence. If the medicine needs to be discontinued after long-term exposure, the prescribing information describes a required procedure for gradual withdrawal (tapering).

Q: Can Zep be used by people who have heart conditions?

A: A comprehensive discussion of one’s full medical history, including heart conditions, is part of the prescribing process. Studies and official information indicate that while the safety profile includes general cautions for patients with certain pre-existing conditions, the data for long-term cardiovascular outcomes for the tirzepatide component is an area that continues to be examined in ongoing research.

Q: Is Zep safe to use if I have kidney issues?

A: Regulatory documents indicate that patients with renal impairment (kidney problems) may require special considerations. This is because the Clobazam/Omeprazole components may be subject to altered clearance from the body. The tirzepatide component also carries a warning about the risk of acute kidney injury due to potential dehydration from gastrointestinal side effects.

Q: Are there any food or drinks that interact with Zep?

A: The medicine has specific requirements related to consumption. Official documents specify administration of the Omeprazole component before food consumption. Furthermore, official product information includes a strong caution against alcohol consumption during use because of a major interaction with the Clobazam component, which can increase the risk of serious side effects like sedation.

Q: Where can I find the official prescribing information for Zep?

A: Official drug information, including the full Prescribing Information or Summary of Product Characteristics, is available from the websites of government regulatory authorities. You can find this information on databases like DailyMed or the official websites of agencies such as the FDA, EMA, or Health Canada.

Q: What happens when a person stops using Zep?

A: Discontinuation of the Clobazam component involves a required process of gradual withdrawal (tapering), as an abrupt stop is generally avoided. This procedure is required by official guidelines to minimize potential adverse effects.

Q: Is Zep a controlled substance?

A: Yes, regulatory authorities have classified the Clobazam component of Zep as a controlled substance. Specifically, it is identified as a Schedule IV medication due to its potential for dependence or misuse.

Q: Can elderly patients use Zep safely?

A: Official documents indicate that older adults may require special consideration, as they may be more susceptible to the CNS-depressant effects of Clobazam and have an increased risk of serious side effects like bone fracture. The prescribing information includes specifications for a lower initial starting dose for the Clobazam component in this patient group.

Q: Why are there different strengths or formulations of Zep?

A: The regulatory documents confirm that the medicine is available in different strengths and forms, such as oral tablets and an oral suspension. This is intended to provide flexibility in the administration and dose adjustments described in the prescribing information.

Q: Does Zep affect my ability to drive or operate machinery?

A: Due to common side effects of the Clobazam component, including somnolence, fatigue, and sedation, official regulatory labels indicate that activities requiring mental alertness, such as driving or operating heavy machinery, are generally reserved until an individual establishes how the medicine affects them.

Q: Has Zep been studied in diverse patient populations?

A: Studies, such as the SURPASS and SURMOUNT programs, involved large, global randomized controlled trials to assess the medicine in adults with the approved conditions. The detailed information about the specific demographic representation within those trials can be found in the full clinical study reports.

Q: What kind of monitoring is recommended when taking Zep?

A: Official guidance indicates that attention to certain laboratory parameters may be appropriate to assess the body’s response. These include blood sugar control, weight, and kidney and liver function. The potential for effects on blood sugar suggests that dose modifications of other glucose-lowering medications may be necessary.

Q: Does taking Zep require a special diet?

A: While the Omeprazole component requires being taken before food, there are no specific blanket 'special diet' rules stated in the regulatory labels. However, consuming high-fat foods or refined carbohydrates may worsen potential gastrointestinal side effects related to the tirzepatide component, so moderation of high-fat foods may be relevant.

Q: How quickly should a person expect Zep to start working?

A: The medicine starts working within hours of administration. Studies and official information indicate that for the tirzepatide component, the initial therapeutic effects on blood sugar and body weight are typically observed around four weeks after starting treatment, with full effects developing over several months.

Q: Do over-the-counter supplements affect how Zep works?

A: Regulatory documents list known prescription drug interactions. However, certain supplements can affect the same liver enzymes (CYP450) that metabolize the Clobazam and Omeprazole components. This suggests that supplements may potentially alter the drug’s effectiveness, and a healthcare provider’s attention to this is part of the prescribing process.

Q: Can Zep be taken with high blood pressure medicine?

A: The Clobazam component may have additive effects in lowering blood pressure when taken with certain antihypertensives (beta-blockers). This could potentially increase symptoms like dizziness or lightheadedness. The potential for these effects indicates a need for attention to blood pressure and related symptoms.

Q: What is the difference between Zep and a generic version?

A: A generic version, when approved by a regulatory body, is required to contain the same active ingredients, dosage form, strength, and route of administration as the brand-name medicine. Official regulatory policy requires generics to meet the same rigorous standards for quality, safety, and effectiveness as the brand name.

Q: Does Zep have a 'Black Box Warning' from the FDA?

A: Yes, the tirzepatide component of Zep carries a Boxed Warning from the FDA. This warning addresses the theoretical risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), which was observed in animal studies.

Q: What happens if Zep is taken with alcohol?

A: The Clobazam component has a major and serious interaction with alcohol. Taking them together can significantly increase the risk of severe side effects, including dangerous central nervous system (CNS) depression and respiratory problems. Official product information includes a strong caution against the consumption of alcohol during use.

Q: Does Zep interact with pain relievers like ibuprofen?

A: No direct pharmacokinetic interaction has been found between the medicine's components and ibuprofen in regulatory studies. However, the Clobazam component is a CNS depressant, so general precaution is appropriate when combining it with other medications that could increase the risk of drowsiness or sedation.

Q: How long does Zep stay in the body after the last use?

A: Official pharmacokinetic reviews indicate that the primary active component of the Clobazam metabolite has a half-life of approximately 59 to 74 hours. Given this prolonged clearance rate, the medicine can take several days to be fully eliminated from the body after the last use.

Q: Does Zep interact with general anesthesia?

A: Yes, the official label for the tirzepatide component includes a warning regarding general anesthesia. Due to the medication's effect of delayed stomach emptying, there is an increased risk of regurgitation during procedures. The prescribing process includes informing a healthcare provider of upcoming procedures. The medicine may be subject to a temporary modification or withholding before surgery.

How should Zep be stored and disposed of?

How to Store and Dispose of Zep

Zep (Clobazam/Omeprazole oral form) must be stored according to regulatory requirements to protect the stability of its components, particularly the moisture-sensitive Omeprazole.

Official Storage Conditions

Requirement Specification
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Container Keep in the original container and ensure the lid is tightly closed to protect from moisture.
Protection Store out of the sight and reach of children. Do not store in areas of excessive heat or moisture.

Disposal Instructions

Unused or expired Zep should not be flushed down the toilet or poured into a sink. The medicine must be disposed of through an authorized drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance, seal it in a plastic bag, and discard it in household trash, following established local guidelines for drug waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zep found in:

A-Z Index: